BPCIA Litigation Updates: Amgen v. Apotex, Immunex v. Sandoz, Janssen v. Celltrion

Amgen v. Apotex (pegfilgrastim)  •  Immunex v. Sandoz (etanercept)  •  Janssen v. Celltrion (infliximab)  •  U.S. Biosimilar Litigation News

A few BPCIA litigation updates to wrap up the week for our readers, looking ahead to next week:

  • The Federal Circuit issued its formal mandate in Amgen v. Apotex yesterday.  With the issuance of the formal mandate, the Federal Circuit has officially ordered that its July  opinion in the case must now be implemented.
  • The scheduling order entered in Immunex v. Sandoz yesterday reflects a stipulated preliminary injunction in the case–see the order here, and the consent preliminary injunction stipulation here.
  • The court in Janssen v. Celltrion will hear oral argument starting next Tuesday, August 16, on the Defendants’ Motion for Summary Judgment as to the ‘471 patent, the parties’ claim construction briefing for the ‘083 patent, and Plaintiffs’ Motion to Expedite Trial.

Stay tuned to the Big Molecule Watch for further updates.

Download PDF

Comments are closed.